{"id":"relugolix","rwe":[],"_fda":{"id":"0d9200dd-878e-4e93-98af-e1149e84c21f","set_id":"077a92f6-9f1b-479a-87c7-c92b5db6aa9c","openfda":{"nui":["N0000175839","N0000175084","N0000008638","N0000190118","N0000187064","N0000190113","N0000185503"],"unii":["P76B05O5V6"],"route":["ORAL"],"rxcui":["2472783","2472789"],"spl_id":["0d9200dd-878e-4e93-98af-e1149e84c21f"],"brand_name":["Orgovyx"],"spl_set_id":["077a92f6-9f1b-479a-87c7-c92b5db6aa9c"],"package_ndc":["72974-120-01","72974-120-97","72974-120-95"],"product_ndc":["72974-120"],"generic_name":["RELUGOLIX"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Decreased GnRH Secretion [PE]"],"substance_name":["RELUGOLIX"],"pharm_class_epc":["Gonadotropin Releasing Hormone Receptor Antagonist [EPC]"],"pharm_class_moa":["Gonadotropin Releasing Hormone Receptor Antagonists [MoA]","Cytochrome P450 3A Inducers [MoA]","Cytochrome P450 2B6 Inducers [MoA]","Breast Cancer Resistance Protein Inhibitors [MoA]","P-Glycoprotein Inhibitors [MoA]"],"manufacturer_name":["Sumitomo Pharma America, Inc."],"application_number":["NDA214621"],"is_original_packager":[true]},"version":"12","pregnancy":["8.1 Pregnancy Risk Summary The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female [see Clinical Pharmacology ( 12.1 )] . There are no human data on the use of ORGOVYX in pregnant females to inform the drug-associated risk. In an animal reproduction study, oral administration of relugolix to pregnant rabbits during organogenesis caused embryo-fetal lethality at maternal exposures that were 0.3 times the human exposure at the recommended dose of 120 mg daily based on AUC ( see Data ). Advise patients of the potential risk to the fetus. Data Animal Data In an embryo-fetal development study, oral administration of relugolix to pregnant rabbits during the period of organogenesis resulted in abortion, total litter loss, or decreased number of live fetuses at a dose of 9 mg/kg/day (approximately 0.3 times the human exposure at the recommended dose of 120 mg daily based on AUC)."],"description":["11 DESCRIPTION Relugolix is a nonpeptide small molecule, GnRH receptor antagonist. The chemical name is N-(4-{1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}phenyl)-N'-methoxyurea. The molecular weight is 623.63 daltons and the molecular formula is C 29 H 27 F 2 N 7 O 5 S. The structural formula is: Relugolix is a white to off-white to slightly yellow solid with a solubility of 0.04 mg per mL in water at 25°C. ORGOVYX is provided as film-coated tablets for oral administration. Each tablet contains 120 mg of relugolix. The inactive ingredients are mannitol, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide, ferric oxide red, and carnauba wax. Structural Formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied The 120 mg tablets are film-coated, light red, almond shaped, and debossed with “R” on one side and “120” on the other side and are supplied in two configurations, bottles and blister packs. Each bottle (NDC 72974-120-01) contains 30 tablets and a desiccant and is closed with a child resistant induction seal cap. The blister cards contain nine tablets packaged in a carton (NDC 72974-120-02). Each ORGOVYX tablet contains 120 mg of relugolix. Storage and Handling Store ORGOVYX at room temperature. Do not store above 30°C (86°F). Dispense to patients in original container only. For bottles, keep container tightly closed after first opening. Keep out of reach of children.","How Supplied The 120 mg tablets are film-coated, light red, almond shaped, and debossed with “R” on one side and “120” on the other side and are supplied in two configurations, bottles and blister packs. Each bottle (NDC 72974-120-01) contains 30 tablets and a desiccant and is closed with a child resistant induction seal cap. The blister cards contain nine tablets packaged in a carton (NDC 72974-120-02). Each ORGOVYX tablet contains 120 mg of relugolix."],"geriatric_use":["8.5 Geriatric Use Of the 622 patients who received ORGOVYX in the HERO study, 81% were 65 years of age or older, while 35% were 75 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. There was no clinically relevant impact of age on the pharmacokinetics of ORGOVYX or testosterone response based on population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses in men 45 to 91 years of age."],"pediatric_use":["8.4 Pediatric Use The safety and efficacy of ORGOVYX in pediatric patients have not been established."],"effective_time":"20251010","clinical_studies":["14 CLINICAL STUDIES HERO Study The safety and efficacy of ORGOVYX was evaluated in HERO (NCT03085095), a randomized, open label study in men with advanced prostate cancer requiring at least 1 year of androgen deprivation therapy and defined as biochemical (PSA) or clinical relapse following local primary intervention, newly diagnosed castration-sensitive metastatic disease, or advanced localized disease. A total of 934 patients were randomized to receive ORGOVYX or leuprolide in a 2:1 ratio for 48 weeks: a) ORGOVYX at a loading dose of 360 mg on the first day followed by daily doses of 120 mg orally. b) Leuprolide acetate 22.5 mg injection (or 11.25 mg in Japan and Taiwan) subcutaneously every 3 months. Leuprolide acetate 11.25 mg is a dosage regimen that is not recommended for this indication in the US. Serum testosterone concentrations were measured at screening; on Days 1, 4, 8, 15, and 29 in the first month; then monthly until the end of the study. The population (N = 930) across both treatment groups had a median age of 71 years (range 47 to 97 years). The ethnic/racial distribution was 68% White, 21% Asian, 4.9% Black, and 5% other. Disease stage was distributed as follows: 32% metastatic (M1), 31% locally advanced (T3/4 NX M0 or any T N1 M0), 28% localized (T1 or T2 N0 M0), and 10% not classifiable. The median testosterone concentration at baseline across the treatment groups was 408 ng/dL. The major efficacy outcome measure was medical castration rate defined as achieving and maintaining serum testosterone suppression to castrate levels (< 50 ng/dL) by Day 29 through 48 weeks of treatment. Other endpoints included castration rates on Day 4 and 15 and castration rates with testosterone < 20 ng/dL at Day 15. The efficacy results are shown in Table 3 and the time course of percent change from baseline in testosterone suppression by ORGOVYX and leuprolide during the 48 week treatment period are shown in Figure 2 . Table 3: Medical Castration Rates (Testosterone Concentrations < 50 ng/dL) from Day 29 through Week 48 in HERO a 11.25 mg is a dosage regimen that is not recommended for this indication in the US. The castration rate of the subgroup of patients receiving 22.5 mg leuprolide (n = 264) was 88.0% (95% CI: 83.4%, 91.4%). b Two patients in each arm did not receive the study treatment and were not included. c Kaplan-Meier estimates within group. ORGOVYX 360/120 mg (N = 622) b Leuprolide Acetate 22.5 or 11.25 mg a (N = 308) b Castration Rate (95% CI) c 96.7% (94.9%, 97.9%) 88.8% (84.6%, 91.8%) Figure 2: Mean (95% CI) Percent Change from Baseline in Testosterone Concentrations from Baseline to Week 49 by Treatment Group in HERO The percentages of patients who attained the medical castration levels of testosterone < 50 ng/dL and < 20 ng/dL within the first 29 days of treatment are summarized in Table 4 and the cumulative incidences of time to testosterone < 50 ng/dL or < 20 ng/dL are shown in Figure 3 . Table 4: Percentage of Patients Attaining Testosterone Decreases within the First 29 Days in HERO a Testosterone < 50 ng/dL Testosterone < 20 ng/dL ORGOVYX (N = 622) Leuprolide Acetate (N = 308) ORGOVYX (N = 622) Leuprolide Acetate (N = 308) a Kaplan-Meier estimates within group. Day 4 56% 0% 7% 0% Day 8 91% 0% 27% 0% Day 15 99% 12% 78% 1% Day 29 99% 82% 95% 57% Figure 3: Cumulative Incidence of Time to Testosterone < 50 ng/dL and < 20 ng/dL in HERO In the clinical trial, PSA levels were monitored and were lowered on average by 65% two weeks after administration of ORGOVYX, 83% after 4 weeks, 92% after 3 months and remained suppressed throughout the 48 weeks of treatment. These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline is related to a clinical benefit. A substudy was conducted in 137 patients who did not receive subsequent androgen deprivation therapy for at least 90 days after discontinuation of ORGOVYX. Based on Kaplan-Meier analyses, 55% of patients achieved testosterone levels above the lower limit of the normal range (> 280 ng/dL) or baseline at 90 days after discontinuation of ORGOVYX. Figure 2 Figure 3 Figure 3"],"laboratory_tests":["5.4 Laboratory Testing Therapy with ORGOVYX results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after ORGOVYX may be affected. The therapeutic effect of ORGOVYX should be monitored by measuring serum concentrations of prostate specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured."],"pharmacodynamics":["12.2 Pharmacodynamics Pituitary and Gonadal Hormones Relugolix reduced LH, FSH ( Figure 1 ), and testosterone concentrations after oral administration of the recommended loading dose of 360 mg and a 120 mg dose once daily. Out of 622 patients, 56% had testosterone concentrations at castrate levels (< 50 ng/dL) by the first sampling timepoint at Day 4, and 97% maintained castrate levels of testosterone through 48 weeks. In a substudy of 137 patients who did not receive subsequent androgen deprivation therapy for at least 90 days after discontinuation of relugolix, the cumulative incidence rate of achieving testosterone concentrations above the lower limit of the normal range (> 280 ng/dL) or baseline at 90 days was 55% [see Clinical Studies ( 14 )] . Figure 1: Mean (± 95% CI) Follicle-Stimulating Hormone and Luteinizing Hormone Concentrations over Time in HERO Figure 1 Cardiac Electrophysiology At a single 60 mg or 360 mg relugolix dose (0.17 or 1 times the recommended loading dose, respectively), clinically significant QTc interval prolongation was not observed."],"pharmacokinetics":["12.3 Pharmacokinetics After administration of single doses ranging from 60 mg to 360 mg (0.17 to 1 times the recommended loading dose), total systemic exposure (AUC) and the maximum concentration (C max ) of relugolix increases in an approximately dose proportional manner. After administration of multiple doses of relugolix once daily, the AUC of relugolix increases in an approximately dose proportional manner while the C max increase is greater than dose proportional for doses from 20 mg to 180 mg (0.17 to 1.5 times the recommended daily dose). After administration of a single 360 mg loading dose, the mean (± standard deviation [± SD]) AUC and C max of relugolix are 985 (± 742) ng.hr/mL and 215 (± 184) ng/mL, respectively. After administration of 120 mg once daily, the mean (± SD) AUC and C max of relugolix at steady-state are 407 (± 168) ng.hr/mL and 70 (± 65) ng/mL, respectively. The accumulation of relugolix upon once daily administration is approximately 2-fold. Absorption Relugolix is a substrate for intestinal P-gp. The mean (CV%) absolute bioavailability of relugolix is 12% (62%). The median (min, max) time to maximum concentration (T max ) of relugolix is 2.25 (0.5, 5.0) hours. Effect of Food No clinically significant differences in the pharmacokinetics of relugolix were observed following administration of a high-calorie, high-fat meal (approximately 800 to 1000 calories with 500, 220, and 124 from fat, carbohydrate, and protein, respectively). Distribution Plasma protein binding of relugolix is 68 to 71%, primarily to albumin and to a lesser extent to α 1 -acid glycoprotein. The mean blood-to-plasma ratio is 0.78. Elimination The mean effective half-life of relugolix is 25 hours and the mean (CV%) terminal elimination half-life is 61 (11%) hours. The mean (CV%) total clearance of relugolix is 29 (15%) L/h and the renal clearance is 8 L/h. Metabolism Relugolix is metabolized primarily by CYP3A and to a lesser extent by CYP2C8. Excretion After oral administration of a single 80 mg radiolabeled dose of relugolix, approximately 81% of the radioactivity was recovered in feces with 4.2% as unchanged and 4.1% in urine with 2.2% as unchanged. Specific Populations No clinically significant differences in the pharmacokinetics of relugolix were observed based on age (45 to 91 years), race/ethnicity (Asian [19%], White [71%], Black/African American [6%]), body weight (41 to 193 kg), mild to severe renal impairment (creatinine clearance [CLcr] 15 to 89 mL/min, as estimated by the Cockcroft-Gault equation), or mild to moderate hepatic impairment (Child-Pugh A or B). The effect of end-stage renal disease with or without hemodialysis or severe hepatic impairment (Child-Pugh C) on the pharmacokinetics of relugolix has not been evaluated. Drug Interactions Studies Clinical Studies Combined P-gp and Moderate CYP3A Inhibitors: Co-administration with erythromycin (P-gp and moderate CYP3A inhibitor) increased the AUC and C max of relugolix by 3.5- and 2.9-fold respectively. Combined P-gp and Strong CYP3A Inducers: Co-administration of relugolix with rifampin (P-gp and strong CYP3A inducer) decreased the AUC and C max of relugolix by 55% and 23%, respectively. Other Drugs: No clinically significant differences in the pharmacokinetics of relugolix were observed when co-administered with voriconazole (strong CYP3A inhibitor), atorvastatin, enzalutamide, or acid-reducing agents. No clinically significant differences in the pharmacokinetics of midazolam (sensitive CYP3A substrate) or rosuvastatin (BCRP substrate), or dabigatran etexilate (P-gp substrate) were observed upon co-administration with relugolix. In Vitro Studies Cytochrome P450 (CYP) Enzymes: Relugolix is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. Relugolix is an inducer of CYP3A and CYP2B6, but not an inducer of CYP1A2. Transporter Systems: Relugolix is a substrate of P-gp, but not a substrate of BCRP. Relugolix is an inhibitor of BCRP and P-gp, but not an inhibitor of OATP1B1, OATP1B3, OATP2B1, OAT1, OAT3, OCT2, MATE1, MATE2-K, or BSEP."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: QT/QTc Interval Prolongation [see Warnings and Precautions ( 5.1 )] . The most common adverse reactions (≥ 10%) and laboratory abnormalities (≥ 15%) were hot flush, glucose increased, triglycerides increased, musculoskeletal pain, hemoglobin decreased, alanine aminotransferase (ALT) increased, fatigue, aspartate aminotransferase (AST) increased, constipation, and diarrhea ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Sumitomo Pharma America, at 1-833-696-8268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ORGOVYX was evaluated in HERO, a randomized (2:1), open-label, clinical study in patients with advanced prostate cancer [see Clinical Studies ( 14 )] . Patients received orally administered ORGOVYX as a loading dose of 360 mg on the first day followed by 120 mg taken orally once daily (n = 622) or received leuprolide acetate administered by depot injection at doses of 22.5 mg (n = 264) or 11.25 mg (n = 44) per local guidelines every 12 weeks (n = 308). Leuprolide acetate 11.25 mg is a dosing regimen that is not recommended for this indication in the US. Among patients who received ORGOVYX, 91% were exposed for at least 48 weeks. Ninety-nine (16%) patients received concomitant radiotherapy and 17 (3%) patients received concomitant enzalutamide with ORGOVYX. Serious adverse reactions occurred in 12% of patients receiving ORGOVYX. Serious adverse reactions in ≥ 0.5% of patients included myocardial infarction (0.8%), acute kidney injury (0.6%), arrhythmia (0.6%), hemorrhage (0.6%), and urinary tract infection (0.5%). Fatal adverse reactions occurred in 0.8% of patients receiving ORGOVYX including metastatic lung cancer (0.3%), myocardial infarction (0.3%), and acute kidney injury (0.2%). Fatal and non-fatal myocardial infarction and stroke were reported in 2.7% of patients receiving ORGOVYX. Permanent discontinuation of ORGOVYX due to an adverse reaction occurred in 3.5% of patients. Adverse reactions which resulted in permanent discontinuation of ORGOVYX in ≥ 0.3 % of patients included atrioventricular block (0.3%), cardiac failure (0.3%), hemorrhage (0.3%), increased transaminases (0.3%), abdominal pain (0.3%), and pneumonia (0.3%). Dosage interruptions of ORGOVYX due to an adverse reaction occurred in 2.7% of patients. Adverse reactions which required dosage interruption in ≥ 0.3% of patients included fracture (0.3%). The most common adverse reactions (≥ 10%) and laboratory abnormalities (≥ 15%) were hot flush (54%), glucose increased (44%), triglycerides increased (35%), musculoskeletal pain (30%), hemoglobin decreased (28%), alanine aminotransferase increased (ALT) (27%), fatigue (26%), aspartate aminotransferase increased (AST) (18%), constipation (12%), and diarrhea (12%). Table 1 summarizes the adverse reactions in HERO. Table 1: Adverse Reactions ( ≥ 10%) of Patients with Advanced Prostate Cancer Who Received ORGOVYX in HERO a Includes arthralgia, back pain, pain in extremity, musculoskeletal pain, myalgia, bone pain, neck pain, arthritis, musculoskeletal stiffness, non-cardiac chest pain, musculoskeletal chest pain, spinal pain, and musculoskeletal discomfort. b Includes fatigue and asthenia. c Includes diarrhea and colitis. Adverse Reaction ORGOVYX N = 622 Leuprolide Acetate N = 308 All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) Vascular disorders Hot flush 54 0.6 52 0 Musculoskeletal and connective tissue disorders Musculoskeletal pain a 30 1.1 29 1.6 General Fatigue b 26 0.3 24 0 Gastrointestinal disorders Diarrhea c 12 0.2 7 0 Constipation 12 0 10 0 Clinically relevant adverse reactions in < 10% of patients who received ORGOVYX included increased weight, insomnia, gynecomastia, hyperhidrosis, depression, decreased libido, and angioedema. Table 2 summarizes the laboratory abnormalities in HERO. Table 2: Select Laboratory Abnormalities ( ≥ 15%) That Worsened from Baseline in Patients with Advanced Prostate Cancer Who Received ORGOVYX in HERO Laboratory Test ORGOVYX a Leuprolide Acetate a All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) a The denominator used to calculate the rate varied from 611 to 619 in the ORGOVYX arm and from 301 to 306 in the leuprolide arm based on the number of patients with a baseline value and at least one post-treatment value. Chemistry Glucose increased 44 2.9 54 6 Triglycerides increased 35 2 36 0.7 ALT increased 27 0.3 28 0 AST increased 18 0 19 0.3 Hematology Hemoglobin decreased 28 0.5 29 0.7 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ORGOVYX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune system disorders: hypersensitivity, including angioedema and urticaria."],"contraindications":["4 CONTRAINDICATIONS ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components. Known severe hypersensitivity to relugolix or to any of the product components ( 4 )."],"drug_interactions":["7 DRUG INTERACTIONS P-gp Inhibitors: Avoid co-administration. If unavoidable, take ORGOVYX first, separate dosing by at least 6 hours, and monitor patients more frequently for adverse reactions ( 2.2 , 7.1 ). Combined P-gp and Strong CYP3A Inducers: Avoid co-administration. If unavoidable, increase the ORGOVYX dose to 240 mg once daily ( 2.3 , 7.1 ). 7.1 Effect of Other Drugs on ORGOVYX P-gp Inhibitors Relugolix is a P-gp substrate. Co-administration of ORGOVYX with an oral P-gp inhibitor increases relugolix exposure [see Clinical Pharmacology ( 12.3 )], which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration with an oral P-gp inhibitor cannot be avoided, take ORGOVYX first and separate dosing by at least 6 hours. Monitor patients for increased adverse reactions [see Dosage and Administration ( 2.2 )] . Treatment with ORGOVYX may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is required. Resume ORGOVYX after the P-gp inhibitor is discontinued. If treatment with ORGOVYX is interrupted for greater than 7 days, restart ORGOVYX with a loading dose of 360 mg on the first day and continue with a dose of 120 mg once daily. Combined P-gp and Strong CYP3A Inducers Relugolix is a P-gp and CYP3A substrate. Co-administration of ORGOVYX with a combined P-gp and strong CYP3A inducer decreases relugolix exposure, which may reduce the effects of ORGOVYX [see Clinical Pharmacology ( 12.3 )]. Avoid co-administration of ORGOVYX with combined P-gp and strong CYP3A inducers. If co-administration cannot be avoided, increase the ORGOVYX dose. After discontinuation of the combined P-gp and strong CYP3A inducer, resume ORGOVYX once daily at the same dose [see Dosage and Administration ( 2.3 )] ."],"mechanism_of_action":["12.1 Mechanism of Action Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone."],"storage_and_handling":["Storage and Handling Store ORGOVYX at room temperature. Do not store above 30°C (86°F). Dispense to patients in original container only. For bottles, keep container tightly closed after first opening. Keep out of reach of children."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone. 12.2 Pharmacodynamics Pituitary and Gonadal Hormones Relugolix reduced LH, FSH ( Figure 1 ), and testosterone concentrations after oral administration of the recommended loading dose of 360 mg and a 120 mg dose once daily. Out of 622 patients, 56% had testosterone concentrations at castrate levels (< 50 ng/dL) by the first sampling timepoint at Day 4, and 97% maintained castrate levels of testosterone through 48 weeks. In a substudy of 137 patients who did not receive subsequent androgen deprivation therapy for at least 90 days after discontinuation of relugolix, the cumulative incidence rate of achieving testosterone concentrations above the lower limit of the normal range (> 280 ng/dL) or baseline at 90 days was 55% [see Clinical Studies ( 14 )] . Figure 1: Mean (± 95% CI) Follicle-Stimulating Hormone and Luteinizing Hormone Concentrations over Time in HERO Figure 1 Cardiac Electrophysiology At a single 60 mg or 360 mg relugolix dose (0.17 or 1 times the recommended loading dose, respectively), clinically significant QTc interval prolongation was not observed. 12.3 Pharmacokinetics After administration of single doses ranging from 60 mg to 360 mg (0.17 to 1 times the recommended loading dose), total systemic exposure (AUC) and the maximum concentration (C max ) of relugolix increases in an approximately dose proportional manner. After administration of multiple doses of relugolix once daily, the AUC of relugolix increases in an approximately dose proportional manner while the C max increase is greater than dose proportional for doses from 20 mg to 180 mg (0.17 to 1.5 times the recommended daily dose). After administration of a single 360 mg loading dose, the mean (± standard deviation [± SD]) AUC and C max of relugolix are 985 (± 742) ng.hr/mL and 215 (± 184) ng/mL, respectively. After administration of 120 mg once daily, the mean (± SD) AUC and C max of relugolix at steady-state are 407 (± 168) ng.hr/mL and 70 (± 65) ng/mL, respectively. The accumulation of relugolix upon once daily administration is approximately 2-fold. Absorption Relugolix is a substrate for intestinal P-gp. The mean (CV%) absolute bioavailability of relugolix is 12% (62%). The median (min, max) time to maximum concentration (T max ) of relugolix is 2.25 (0.5, 5.0) hours. Effect of Food No clinically significant differences in the pharmacokinetics of relugolix were observed following administration of a high-calorie, high-fat meal (approximately 800 to 1000 calories with 500, 220, and 124 from fat, carbohydrate, and protein, respectively). Distribution Plasma protein binding of relugolix is 68 to 71%, primarily to albumin and to a lesser extent to α 1 -acid glycoprotein. The mean blood-to-plasma ratio is 0.78. Elimination The mean effective half-life of relugolix is 25 hours and the mean (CV%) terminal elimination half-life is 61 (11%) hours. The mean (CV%) total clearance of relugolix is 29 (15%) L/h and the renal clearance is 8 L/h. Metabolism Relugolix is metabolized primarily by CYP3A and to a lesser extent by CYP2C8. Excretion After oral administration of a single 80 mg radiolabeled dose of relugolix, approximately 81% of the radioactivity was recovered in feces with 4.2% as unchanged and 4.1% in urine with 2.2% as unchanged. Specific Populations No clinically significant differences in the pharmacokinetics of relugolix were observed based on age (45 to 91 years), race/ethnicity (Asian [19%], White [71%], Black/African American [6%]), body weight (41 to 193 kg), mild to severe renal impairment (creatinine clearance [CLcr] 15 to 89 mL/min, as estimated by the Cockcroft-Gault equation), or mild to moderate hepatic impairment (Child-Pugh A or B). The effect of end-stage renal disease with or without hemodialysis or severe hepatic impairment (Child-Pugh C) on the pharmacokinetics of relugolix has not been evaluated. Drug Interactions Studies Clinical Studies Combined P-gp and Moderate CYP3A Inhibitors: Co-administration with erythromycin (P-gp and moderate CYP3A inhibitor) increased the AUC and C max of relugolix by 3.5- and 2.9-fold respectively. Combined P-gp and Strong CYP3A Inducers: Co-administration of relugolix with rifampin (P-gp and strong CYP3A inducer) decreased the AUC and C max of relugolix by 55% and 23%, respectively. Other Drugs: No clinically significant differences in the pharmacokinetics of relugolix were observed when co-administered with voriconazole (strong CYP3A inhibitor), atorvastatin, enzalutamide, or acid-reducing agents. No clinically significant differences in the pharmacokinetics of midazolam (sensitive CYP3A substrate) or rosuvastatin (BCRP substrate), or dabigatran etexilate (P-gp substrate) were observed upon co-administration with relugolix. In Vitro Studies Cytochrome P450 (CYP) Enzymes: Relugolix is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. Relugolix is an inducer of CYP3A and CYP2B6, but not an inducer of CYP1A2. Transporter Systems: Relugolix is a substrate of P-gp, but not a substrate of BCRP. Relugolix is an inhibitor of BCRP and P-gp, but not an inhibitor of OATP1B1, OATP1B3, OATP2B1, OAT1, OAT3, OCT2, MATE1, MATE2-K, or BSEP."],"indications_and_usage":["1 INDICATIONS AND USAGE ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer. ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer ( 1 )."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS QT/QTc Interval Prolongation: Androgen deprivation therapy may prolong the QT interval ( 5.1 ). Hypersensitivity: ORGOVYX can cause hypersensitivity reactions, including angioedema. Withhold ORGOVYX in patients who experience symptoms of hypersensitivity. Discontinue ORGOVYX for severe hypersensitivity reactions and manage as clinically indicated ( 5.2 ). Embryo-Fetal Toxicity: ORGOVYX can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception ( 5.3 , 8.1 , 8.3 ). 5.1 QT/QTc Interval Prolongation Androgen deprivation therapy, such as ORGOVYX, may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes [see Clinical Pharmacology ( 12.2 )]. 5.2 Hypersensitivity Reactions ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or any of the product components [see Contraindications ( 4 )] . Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, have been reported postmarketing in patients treated with ORGOVYX. In HERO, patients treated with relugolix reported angioedema (0.2%) [see Clinical Trials Experience ( 6.1 )] . Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue ORGOVYX and promptly seek medical care. Discontinue ORGOVYX for severe hypersensitivity reactions and manage as clinically indicated. 5.3 Embryo-Fetal Toxicity The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female. In an animal reproduction study, oral administration of relugolix to pregnant rabbits during the period of organogenesis caused embryo-fetal lethality at maternal exposures that were 0.3 times the human exposure at the recommended dose of 120 mg daily based on area under the curve (AUC). Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX [see Use in Specific Populations ( 8.1 , 8.3 ) and Clinical Pharmacology ( 12.1 )] . 5.4 Laboratory Testing Therapy with ORGOVYX results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after ORGOVYX may be affected. The therapeutic effect of ORGOVYX should be monitored by measuring serum concentrations of prostate specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured."],"clinical_studies_table":["
Table 3: Medical Castration Rates (Testosterone Concentrations < 50 ng/dL) from Day 29 through Week 48 in HERO
a 11.25 mg is a dosage regimen that is not recommended for this indication in the US. The castration rate of the subgroup of patients receiving 22.5 mg leuprolide (n = 264) was 88.0% (95% CI: 83.4%, 91.4%).
b Two patients in each arm did not receive the study treatment and were not included.
c Kaplan-Meier estimates within group.
ORGOVYX 360/120 mg (N = 622)bLeuprolide Acetate 22.5 or 11.25 mga (N = 308)b
Castration Rate (95% CI)c96.7% (94.9%, 97.9%) 88.8% (84.6%, 91.8%)
","
Table 4: Percentage of Patients Attaining Testosterone Decreases within the First 29 Days in HEROa
Testosterone < 50 ng/dLTestosterone < 20 ng/dL
ORGOVYX (N = 622)Leuprolide Acetate (N = 308)ORGOVYX (N = 622)Leuprolide Acetate (N = 308)
a Kaplan-Meier estimates within group.
Day 4 56% 0% 7% 0%
Day 8 91% 0% 27% 0%
Day 15 99% 12% 78% 1%
Day 29 99% 82% 95% 57%
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Two-year carcinogenicity studies were conducted in mice at oral relugolix doses up to 100 mg/kg/day and in rats at doses up to 600 mg/kg/day. Relugolix was not carcinogenic in mice or rats at exposures up to approximately 75 or 224 times, respectively, the human exposure at the recommended dose of 120 mg daily based on AUC. Relugolix was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay or clastogenic in the in vitro chromosomal aberration assay in Chinese hamster lung cells or the in vivo rat bone marrow micronucleus assay. In human GnRH-receptor knock-in male mice, oral administration of relugolix decreased prostate and seminal vesicle weights at doses ≥ 3 mg/kg twice daily for 28 days. The effects of relugolix were reversible, except for testis weight, which did not fully recover within 28 days after drug withdrawal. In a 39-week repeat-dose toxicity study in monkeys, there were no significant effects on male reproductive organs at oral relugolix doses up to 50 mg/kg/day (approximately 53 times the human exposure at the recommended dose of 120 mg daily based on AUC). 13.2 Animal Toxicology and/or Pharmacology Phospholipidosis (intracellular phospholipid accumulation) was observed in multiple organs and tissues (e.g., liver, pancreas, spleen, kidney, lymph nodes, lung, bone marrow, gastrointestinal tract or testes) after repeated oral administration of relugolix in rats and monkeys. In a rat 26-week toxicity study, phospholipidosis was observed at doses ≥ 100 mg/kg (approximately 18 times the human exposure at the recommended dose based on AUC). In a monkey 39-week toxicity study, this effect was observed at doses ≥ 1.5 mg/kg (approximately 0.6 times the human exposure at the recommended dose based on AUC) and demonstrated evidence of reversibility after cessation of treatment. The significance of this finding in humans is unknown."],"adverse_reactions_table":["
Table 1: Adverse Reactions ( ≥ 10%) of Patients with Advanced Prostate Cancer Who Received ORGOVYX in HERO
a Includes arthralgia, back pain, pain in extremity, musculoskeletal pain, myalgia, bone pain, neck pain, arthritis, musculoskeletal stiffness, non-cardiac chest pain, musculoskeletal chest pain, spinal pain, and musculoskeletal discomfort.
b Includes fatigue and asthenia.
c Includes diarrhea and colitis.
Adverse ReactionORGOVYX N = 622Leuprolide Acetate N = 308
All Grades (%)Grade 3-4 (%)All Grades (%)Grade 3-4 (%)
Vascular disorders
Hot flush 54 0.6 52 0
Musculoskeletal and connective tissue disorders
Musculoskeletal paina30 1.1 29 1.6
General
Fatigueb26 0.3 24 0
Gastrointestinal disorders
Diarrheac12 0.2 7 0
Constipation 12 0 10 0
","
Table 2: Select Laboratory Abnormalities ( ≥ 15%) That Worsened from Baseline in Patients with Advanced Prostate Cancer Who Received ORGOVYX in HERO
Laboratory TestORGOVYXaLeuprolide Acetatea
All Grades (%)Grade 3-4 (%)All Grades (%)Grade 3-4 (%)
a The denominator used to calculate the rate varied from 611 to 619 in the ORGOVYX arm and from 301 to 306 in the leuprolide arm based on the number of patients with a baseline value and at least one post-treatment value.
Chemistry
Glucose increased 44 2.9 54 6
Triglycerides increased 35 2 36 0.7
ALT increased 27 0.3 28 0
AST increased 18 0 19 0.3
Hematology
Hemoglobin decreased 28 0.5 29 0.7
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). QT/QTc Interval Prolongation Advise patients that androgen deprivation therapy treatment with ORGOVYX may prolong the QT interval. Inform patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately for signs or symptoms of QT prolongation [see Warnings and Precautions ( 5.1 )] . Hypersensitivity Inform patients that if they have experienced severe hypersensitivity with relugolix or to any of the product components, ORGOVYX is contraindicated [see Contraindications ( 4 )] . Inform patients that ORGOVYX can cause severe hypersensitivity reactions that include angioedema [see Warnings and Precautions ( 5.2 )]. Advise patients who experience hypersensitivity symptoms to discontinue ORGOVYX and promptly contact their healthcare provider. Androgen Deprivation Inform patients about adverse reactions related to androgen deprivation therapy with ORGOVYX, including hot flashes, flushing of the skin, increased weight, decreased sex drive, and difficulties with erectile function [see Adverse Reactions ( 6.1 )] . Embryo-Fetal Toxicity Inform patients that ORGOVYX can be harmful to a developing fetus and can cause loss of pregnancy. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX [see Warnings and Precautions ( 5.3 ) and Use in Specific Populations ( 8.1 , 8.3 )]. Infertility Inform patients that ORGOVYX may cause infertility [see Use in Specific Populations ( 8.3 )] . Drug Disposal Advise patients to dispose of unused medication via a take-back option if available. Otherwise, advise to follow FDA instructions for disposing medication in the household trash, www.fda.gov/drugdisposal and NOT to flush down the toilet. Manufactured for Sumitomo Pharma America, Inc., Marlborough, MA 01752 214621-MS-006"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended Dosage: A loading dose of 360 mg on the first day of treatment followed by 120 mg taken orally once daily, at approximately the same time each day ( 2.1 ). ORGOVYX can be taken with or without food ( 2.1 , 12.3 ). Instruct patients to swallow tablets whole and not to crush or chew tablets ( 2.1 ). 2.1 Recommended Dosage Initiate treatment of ORGOVYX with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. ORGOVYX can be taken with or without food [see Clinical Pharmacology ( 12.3 )] . Instruct patients to swallow tablets whole and not to crush or chew tablets. Advise patients to take a missed dose of ORGOVYX as soon as they remember. If the dose was missed by more than 12 hours, patients should not take the missed dose and resume with the next scheduled dose. If treatment with ORGOVYX is interrupted for greater than 7 days, restart ORGOVYX with a loading dose of 360 mg on the first day, and continue with a dose of 120 mg once daily. In patients treated with GnRH receptor agonists and antagonists for prostate cancer, treatment is usually continued upon development of nonmetastatic or metastatic castration-resistant prostate cancer. 2.2 Dosage Modifications for P-gp Inhibitors Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration is unavoidable, take ORGOVYX first and separate dosing by at least 6 hours [ see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 ) ] . Monitor patients for increased adverse reactions. Treatment with ORGOVYX may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is required. Resume ORGOVYX after the P-gp inhibitor is discontinued. If treatment with ORGOVYX is interrupted for greater than 7 days, restart ORGOVYX with a loading dose of 360 mg on the first day and continue with a dose of 120 mg once daily. 2.3 Dosage Modifications for Combined P-gp and Strong CYP3A Inducers Avoid co-administration of ORGOVYX with combined P-gp and strong CYP3A inducers. If co-administration is unavoidable, increase the ORGOVYX dose to 240 mg once daily. After discontinuation of the combined P-gp and strong CYP3A inducer, resume the recommended ORGOVYX dose of 120 mg once daily [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] ."],"spl_product_data_elements":["Orgovyx relugolix relugolix relugolix MANNITOL SODIUM STARCH GLYCOLATE TYPE A HYDROXYPROPYL CELLULOSE (90000 WAMW) MAGNESIUM STEARATE HYPROMELLOSE 2910 (6 MPA.S) TITANIUM DIOXIDE FERRIC OXIDE RED CARNAUBA WAX light red almond R;120"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets: 120 mg, light red, almond-shaped, film-coated, and debossed with “R” on one side and “120” on the other side. Tablets: 120 mg ( 3 )."],"spl_patient_package_insert":["This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 08/2023 PATIENT INFORMATION ORGOVYX (or-GO-vix) (relugolix) Tablets What is ORGOVYX? ORGOVYX is a prescription medicine used in adults for the treatment of advanced prostate cancer. It is not known if ORGOVYX is safe or effective in females. It is not known if ORGOVYX is safe or effective in children. Do not take ORGOVYX if you have had a severe allergic reaction to relugolix or any of the ingredients in ORGOVYX. See the end of this Patient Information for a complete list of the ingredients in ORGOVYX. Before taking ORGOVYX, tell your healthcare provider about all of your medical conditions, including if you: have any heart problems, including a condition called long QT syndrome. are pregnant or plan to become pregnant. ORGOVYX can harm your unborn baby and cause loss of pregnancy (miscarriage). have a partner who is pregnant or may become pregnant. Males who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with ORGOVYX and for 2 weeks after the last dose of ORGOVYX. are breastfeeding or plan to breastfeed. It is not known if ORGOVYX passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking ORGOVYX with certain other medicines can affect how ORGOVYX works or may cause side effects. You should not start or stop any medicine before you talk with your healthcare provider who prescribed ORGOVYX. Know the medicines you take. Keep a list of them with you to show to your healthcare provider and pharmacist when you get a new medicine. How should I take ORGOVYX? Take ORGOVYX exactly as your healthcare provider tells you. Take 3 ORGOVYX tablets on your first day of treatment. After that, take 1 ORGOVYX tablet each day. Take ORGOVYX at about the same time each day. Take ORGOVYX with or without food. Swallow ORGOVYX tablets whole. Do not crush or chew tablets. Your healthcare provider may change your dose if needed. Do not change your dose or stop taking ORGOVYX without talking with your healthcare provider first. If you miss a dose of ORGOVYX, take it as soon as you remember. If the dose was missed by more than 12 hours, the missed dose should not be taken. Take your next dose at your regular time the next day. What are the possible side effects of ORGOVYX? ORGOVYX may cause serious side effects, including: Changes in the electrical activity of your heart (QT prolongation). Your healthcare provider may check your body salts (electrolytes) and the electrical activity of your heart during treatment with ORGOVYX. Tell your healthcare provider right away if you get any signs or symptoms of QT prolongation, including: dizziness fainting feeling that your heart is pounding or racing (palpitations) chest pain Allergic reactions. Stop taking ORGOVYX and tell your healthcare provider or get emergency medical help right away if you get any signs or symptoms of an allergic reaction, including: swelling of your face, lips, tongue, throat, or trouble swallowing trouble breathing hives (raised bumps), rash, or redness all over your body The most common side effects of ORGOVYX include: hot flushes increased blood sugar levels increased blood fat (triglyceride) levels muscle and joint pain decreased blood hemoglobin levels increased liver enzymes tiredness constipation diarrhea Other side effects include weight gain, decreased sex drive, and erectile function problems. ORGOVYX may cause fertility problems in males, which may affect your ability to father children. Talk to your healthcare provider if this is a concern for you. These are not all the possible side effects of ORGOVYX. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store ORGOVYX? Store ORGOVYX at room temperature. Do not store ORGOVYX above 86°F (30°C). Keep the bottle tightly closed after you first open it. The ORGOVYX bottle contains a desiccant to help keep your medicine dry (protect it from moisture). Do not remove the desiccant from the bottle. Dispose of unused medicines through community take-back disposal programs when available. If no community take-back disposal program is available go to www.fda.gov/drugdisposal for information on how to dispose of ORGOVYX the right way. Do not flush ORGOVYX down the toilet. Keep ORGOVYX and all medicines out of the reach of children. General information about the safe and effective use of ORGOVYX. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ORGOVYX for a condition for which it was not prescribed. Do not give ORGOVYX to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ORGOVYX that is written for health professionals. What are the ingredients in ORGOVYX? Active ingredient: relugolix Inactive ingredients: mannitol, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide, ferric oxide red, and carnauba wax. Manufactured for: Sumitomo Pharma America, Inc., Marlborough, MA 01752 For more information, go to www.orgovyx.com or call 1-833-696-8268. 214621-MS-005"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female [see Clinical Pharmacology ( 12.1 )] . There are no human data on the use of ORGOVYX in pregnant females to inform the drug-associated risk. In an animal reproduction study, oral administration of relugolix to pregnant rabbits during organogenesis caused embryo-fetal lethality at maternal exposures that were 0.3 times the human exposure at the recommended dose of 120 mg daily based on AUC ( see Data ). Advise patients of the potential risk to the fetus. Data Animal Data In an embryo-fetal development study, oral administration of relugolix to pregnant rabbits during the period of organogenesis resulted in abortion, total litter loss, or decreased number of live fetuses at a dose of 9 mg/kg/day (approximately 0.3 times the human exposure at the recommended dose of 120 mg daily based on AUC). 8.2 Lactation Risk Summary The safety and efficacy of ORGOVYX have not been established in females. Relugolix was detected in human breast milk ( see Data ). There are no data on the effects of relugolix or its metabolites on the breastfed child, or the effects on milk production. Data In a milk-only lactation study in 8 healthy adult lactating women, the mean total amount of relugolix recovered in human breast milk over the first 24 hours was 0.003 mg and over 120 hours (5 days) was 0.004 mg following a single, oral, maternal dose of 40 mg. The mean calculated daily infant dose was 0.0006 mg/kg/day using 0.003 mg (the amount recovered in human breast milk over the first 24 hours). The relative infant dose was 0.1% of the maternal weight-adjusted dose of 40 mg. 8.3 Females and Males of Reproductive Potential Contraception Males Based on findings in animals and mechanism of action, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX [see Use in Specific Populations ( 8.1 )]. Infertility Males Based on findings in animals and mechanism of action, ORGOVYX may impair fertility in males of reproductive potential [see Clinical Pharmacology ( 12.1 ) and Nonclinical Toxicology ( 13.1 )]. 8.4 Pediatric Use The safety and efficacy of ORGOVYX in pediatric patients have not been established. 8.5 Geriatric Use Of the 622 patients who received ORGOVYX in the HERO study, 81% were 65 years of age or older, while 35% were 75 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. There was no clinically relevant impact of age on the pharmacokinetics of ORGOVYX or testosterone response based on population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses in men 45 to 91 years of age."],"spl_patient_package_insert_table":["
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 08/2023
PATIENT INFORMATION ORGOVYX (or-GO-vix) (relugolix) Tablets
What is ORGOVYX? ORGOVYX is a prescription medicine used in adults for the treatment of advanced prostate cancer. It is not known if ORGOVYX is safe or effective in females. It is not known if ORGOVYX is safe or effective in children.
Do not take ORGOVYX if you have had a severe allergic reaction to relugolix or any of the ingredients in ORGOVYX. See the end of this Patient Information for a complete list of the ingredients in ORGOVYX.
Before taking ORGOVYX, tell your healthcare provider about all of your medical conditions, including if you: have any heart problems, including a condition called long QT syndrome. are pregnant or plan to become pregnant. ORGOVYX can harm your unborn baby and cause loss of pregnancy (miscarriage). have a partner who is pregnant or may become pregnant.Males who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with ORGOVYX and for 2 weeks after the last dose of ORGOVYX. are breastfeeding or plan to breastfeed. It is not known if ORGOVYX passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking ORGOVYX with certain other medicines can affect how ORGOVYX works or may cause side effects. You should not start or stop any medicine before you talk with your healthcare provider who prescribed ORGOVYX. Know the medicines you take. Keep a list of them with you to show to your healthcare provider and pharmacist when you get a new medicine.
How should I take ORGOVYX? Take ORGOVYX exactly as your healthcare provider tells you. Take 3 ORGOVYX tablets on your first day of treatment. After that, take 1 ORGOVYX tablet each day. Take ORGOVYX at about the same time each day. Take ORGOVYX with or without food. Swallow ORGOVYX tablets whole. Do not crush or chew tablets. Your healthcare provider may change your dose if needed. Do not change your dose or stop taking ORGOVYX without talking with your healthcare provider first.If you miss a dose of ORGOVYX, take it as soon as you remember. If the dose was missed by more than 12 hours, the missed dose should not be taken. Take your next dose at your regular time the next day.
What are the possible side effects of ORGOVYX? ORGOVYX may cause serious side effects, including: Changes in the electrical activity of your heart (QT prolongation). Your healthcare provider may check your body salts (electrolytes) and the electrical activity of your heart during treatment with ORGOVYX. Tell your healthcare provider right away if you get any signs or symptoms of QT prolongation, including:
dizziness fainting feeling that your heart is pounding or racing (palpitations) chest pain
Allergic reactions. Stop taking ORGOVYX and tell your healthcare provider or get emergency medical help right away if you get any signs or symptoms of an allergic reaction, including:
swelling of your face, lips, tongue, throat, or trouble swallowing trouble breathing hives (raised bumps), rash, or redness all over your body
The most common side effects of ORGOVYX include:
hot flushes increased blood sugar levels increased blood fat (triglyceride) levels muscle and joint pain decreased blood hemoglobin levels increased liver enzymes tiredness constipation diarrhea
Other side effects include weight gain, decreased sex drive, and erectile function problems. ORGOVYX may cause fertility problems in males, which may affect your ability to father children. Talk to your healthcare provider if this is a concern for you. These are not all the possible side effects of ORGOVYX. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ORGOVYX? Store ORGOVYX at room temperature. Do not store ORGOVYX above 86°F (30°C). Keep the bottle tightly closed after you first open it. The ORGOVYX bottle contains a desiccant to help keep your medicine dry (protect it from moisture). Do not remove the desiccant from the bottle. Dispose of unused medicines through community take-back disposal programs when available. If no community take-back disposal program is available go to www.fda.gov/drugdisposal for information on how to dispose of ORGOVYX the right way. Do not flush ORGOVYX down the toilet.
Keep ORGOVYX and all medicines out of the reach of children.
General information about the safe and effective use of ORGOVYX. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ORGOVYX for a condition for which it was not prescribed. Do not give ORGOVYX to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ORGOVYX that is written for health professionals.
What are the ingredients in ORGOVYX? Active ingredient: relugolix Inactive ingredients: mannitol, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide, ferric oxide red, and carnauba wax. Manufactured for: Sumitomo Pharma America, Inc., Marlborough, MA 01752 For more information, go to www.orgovyx.com or call 1-833-696-8268.
","
dizziness fainting feeling that your heart is pounding or racing (palpitations) chest pain
","
swelling of your face, lips, tongue, throat, or trouble swallowing trouble breathing hives (raised bumps), rash, or redness all over your body
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Phospholipidosis (intracellular phospholipid accumulation) was observed in multiple organs and tissues (e.g., liver, pancreas, spleen, kidney, lymph nodes, lung, bone marrow, gastrointestinal tract or testes) after repeated oral administration of relugolix in rats and monkeys. In a rat 26-week toxicity study, phospholipidosis was observed at doses ≥ 100 mg/kg (approximately 18 times the human exposure at the recommended dose based on AUC). In a monkey 39-week toxicity study, this effect was observed at doses ≥ 1.5 mg/kg (approximately 0.6 times the human exposure at the recommended dose based on AUC) and demonstrated evidence of reversibility after cessation of treatment. The significance of this finding in humans is unknown."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 120 mg Tablet Bottle Label NDC 72974-120-01 Rx only ORGOVYX ® (relugolix) tablets 120 mg 30 tablets PRINCIPAL DISPLAY PANEL - 120 mg Tablet Bottle Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Two-year carcinogenicity studies were conducted in mice at oral relugolix doses up to 100 mg/kg/day and in rats at doses up to 600 mg/kg/day. Relugolix was not carcinogenic in mice or rats at exposures up to approximately 75 or 224 times, respectively, the human exposure at the recommended dose of 120 mg daily based on AUC. Relugolix was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay or clastogenic in the in vitro chromosomal aberration assay in Chinese hamster lung cells or the in vivo rat bone marrow micronucleus assay. In human GnRH-receptor knock-in male mice, oral administration of relugolix decreased prostate and seminal vesicle weights at doses ≥ 3 mg/kg twice daily for 28 days. The effects of relugolix were reversible, except for testis weight, which did not fully recover within 28 days after drug withdrawal. In a 39-week repeat-dose toxicity study in monkeys, there were no significant effects on male reproductive organs at oral relugolix doses up to 50 mg/kg/day (approximately 53 times the human exposure at the recommended dose of 120 mg daily based on AUC)."]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"HOT FLUSH","source":"FDA FAERS","actionTaken":"7152 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"5481 reports"},{"date":"","signal":"THERAPY INTERRUPTED","source":"FDA FAERS","actionTaken":"3747 reports"},{"date":"","signal":"INCORRECT DOSE ADMINISTERED","source":"FDA FAERS","actionTaken":"1955 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"1826 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"1471 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1450 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"1260 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"1239 reports"},{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"963 reports"}],"drugInteractions":[{"drug":"P-gp Inhibitors","action":"Avoid","effect":"Increases relugolix exposure"},{"drug":"P-gp Inhibitors","action":"Monitor","effect":"Increases risk of adverse reactions"},{"drug":"P-gp Inhibitors","action":"Monitor","effect":"Increases risk of adverse reactions"},{"drug":"Combined P-gp and Strong CYP3A Inducers","action":"Avoid","effect":"Decreases relugolix exposure"},{"drug":"Combined P-gp and Strong CYP3A Inducers","action":"Avoid","effect":"Reduces effects of ORGOVYX"},{"drug":"P-gp Inhibitors","action":"Monitor","effect":"Increases risk of adverse reactions"},{"drug":"Combined P-gp and Strong CYP3A Inducers","action":"Adjust dose","effect":"Decreases relugolix exposure"}],"commonSideEffects":[{"effect":"Hot flush","drugRate":"54%","severity":"mild","_validated":true},{"effect":"Glucose increased","drugRate":"44%","severity":"mild","_validated":true},{"effect":"Triglycerides increased","drugRate":"35%","severity":"mild","_validated":true},{"effect":"Musculoskeletal pain","drugRate":"30%","severity":"mild","_validated":true},{"effect":"Hemoglobin decreased","drugRate":"28%","severity":"mild","_validated":true},{"effect":"Alanine aminotransferase increased (ALT)","drugRate":"27%","severity":"mild","_validated":true},{"effect":"Fatigue","drugRate":"26%","severity":"mild","_validated":true},{"effect":"Aspartate aminotransferase increased (AST)","drugRate":"18%","severity":"mild","_validated":true},{"effect":"Constipation","drugRate":"12%","severity":"mild","_validated":true},{"effect":"Diarrhea","drugRate":"12%","severity":"mild","_validated":true},{"effect":"Myocardial infarction","drugRate":"0.8%","severity":"serious","_validated":true},{"effect":"Acute kidney injury","drugRate":"0.6%","severity":"serious","_validated":true},{"effect":"Arrhythmia","drugRate":"0.6%","severity":"serious","_validated":true},{"effect":"Hemorrhage","drugRate":"0.6%","severity":"serious","_validated":true},{"effect":"Urinary tract infection","drugRate":"0.5%","severity":"serious","_validated":true},{"effect":"Atrioventricular block","drugRate":"0.3%","severity":"serious","_validated":true},{"effect":"Cardiac failure","drugRate":"0.3%","severity":"serious","_validated":true},{"effect":"Pneumonia","drugRate":"0.3%","severity":"serious","_validated":true},{"effect":"Fracture","drugRate":"0.3%","severity":"serious","_validated":true}],"contraindications":["4 CONTRAINDICATIONS ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components. Known severe hypersensitivity to relugolix or to any of the product components ( 4 )."],"specialPopulations":{"Pregnancy":"The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female. There are no human data on the use of ORGOVYX in pregnant females to inform the drug-associated risk. In an animal reproduction study, oral administration of relugolix to pregnant rabbits during organogenesis caused embryo-fetal lethality at maternal exposures that were 0.3 times the human exposure at the recommended dose of 120 mg daily based on AUC.","Geriatric use":"Of the 622 patients who received ORGOVYX in the HERO study, 81% were 65 years of age or older, while 35% were 75 years of age or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. There was no clinically relevant impact of age on the pharmacokinetics of ORGOVYX or testosterone response based on population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses in men 45 to 91 years of age.","Paediatric use":"The safety and efficacy of ORGOVYX in pediatric patients have not been established.","Renal impairment":"Not mentioned","Hepatic impairment":"Not mentioned"}},"trials":[],"aliases":[],"company":"MYOVANT SCIENCES","patents":[{"source":"DrugCentral Orange Book","expires":"2037-09-29","patentNumber":"10449191"},{"source":"DrugCentral Orange Book","expires":"2037-09-29","patentNumber":"10786501"},{"source":"DrugCentral Orange Book","expires":"2037-09-29","patentNumber":"11033551"},{"source":"DrugCentral Orange Book","expires":"2037-09-29","patentNumber":"11583526"},{"source":"DrugCentral Orange Book","expires":"2036-02-25","patentNumber":"10350170"},{"source":"DrugCentral Orange Book","expires":"2024-02-17","patentNumber":"9346822"},{"source":"DrugCentral Orange Book","expires":"2024-02-04","patentNumber":"8735401"},{"source":"DrugCentral Orange Book","expires":"2024-01-28","patentNumber":"7300935"},{"source":"DrugCentral Orange Book","expires":"2024-01-28","patentNumber":"8058280"},{"type":"Method of Use","number":"12144809","applicant":"SUMITOMO PHARMA AMERICA INC","territory":"US","tradeName":"ORGOVYX","expiryDate":"2037-09-29"},{"type":"Method of Use","number":"12336990","applicant":"SUMITOMO PHARMA AMERICA INC","territory":"US","tradeName":"ORGOVYX","expiryDate":"2037-09-29"},{"type":"Method of Use","number":"12097198","applicant":"SUMITOMO PHARMA AMERICA INC","territory":"US","tradeName":"ORGOVYX","expiryDate":"2037-09-29"},{"type":"Compound","number":"11795178","applicant":"SUMITOMO PHARMA AMERICA INC","territory":"US","tradeName":"ORGOVYX","expiryDate":"2033-09-27"},{"type":"Compound","number":"12325714","applicant":"SUMITOMO PHARMA AMERICA INC","territory":"US","tradeName":"ORGOVYX","expiryDate":"2033-09-27"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=relugolix","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:44:12.878381+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:44:12.878046+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Relugolix","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:44:27.000765+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:44:25.649425+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:44:12.896880+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:44:11.294938+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=relugolix","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:44:26.446870+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:44:10.232291+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:44:10.232347+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:44:10.232364+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:44:27.998447+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Gonadotropin-releasing hormone receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:44:27.000334+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1800159/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:44:26.907016+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA214621","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:44:10.232375+00:00"}},"allNames":"orgovyx","offLabel":[],"synonyms":["relugolix","TAK-385","orgovyx","relumina","RVT 601"],"timeline":[{"date":"2004-01-01","type":"neutral","_source":"Wikipedia","milestone":"Relugolix first described","regulator":"none"},{"date":"2020-12-18","type":"positive","_source":"Wikipedia","milestone":"Relugolix approved for prostate cancer treatment in the United States","regulator":"FDA"},{"date":"2020-12-18","type":"positive","_source":"FDA NDA214621","milestone":"FDA ORIG — SUMITOMO PHARMA AM","regulator":"FDA","description":""},{"date":"2021-05-26","type":"positive","_source":"FDA NDA214846","milestone":"FDA ORIG — SUMITOMO PHARMA AM","regulator":"FDA","description":""},{"date":"2022-02-01","type":"positive","_source":"Wikipedia","milestone":"CHMP adopted a positive opinion for Orgovyx","regulator":"EMA"},{"date":"2022-04-01","type":"positive","_source":"Wikipedia","milestone":"Relugolix approved for medical use in the European Union","regulator":"EMA"},{"date":"2022-08-05","type":"positive","_source":"FDA NDA214846","milestone":"FDA SUPPL — SUMITOMO PHARMA AM","regulator":"FDA","description":""},{"date":"2023-01-27","type":"positive","_source":"FDA NDA214846","milestone":"FDA SUPPL — SUMITOMO PHARMA AM","regulator":"FDA","description":""},{"date":"2024-08-01","type":"neutral","_source":"Wikipedia","milestone":"Relugolix available in NHS England","regulator":"none"},{"date":"2024-04-30","type":"positive","_source":"FDA NDA214846","milestone":"FDA SUPPL — SUMITOMO PHARMA AM","regulator":"FDA","description":""},{"date":"2025-08-27","type":"positive","_source":"FDA NDA214846","milestone":"FDA SUPPL — SUMITOMO PHARMA AM","regulator":"FDA","description":""}],"_dailymed":{"setId":"077a92f6-9f1b-479a-87c7-c92b5db6aa9c","title":"ORGOVYX (RELUGOLIX) TABLET, FILM COATED [SUMITOMO PHARMA AMERICA, INC.]","labeler":""},"aiSummary":"Orgovyx, developed by Pfizer Inc., is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors. This reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone. Orgovyx is used in the treatment of prostate cancer, uterine fibroids, and endometriosis. It is taken by mouth and has shown significant clinical differentiation in its mechanism of action. Orgovyx has achieved commercial significance with revenue of $21.2B and has a strong presence in the market. Pfizer Inc. continues to develop its pipeline, with Orgovyx being a key player in the company's portfolio.","brandName":"Orgovyx","ecosystem":[],"mechanism":{"target":"Gonadotropin-releasing hormone receptor","novelty":"first-in-class","targets":[{"gene":"GNRHR","source":"DrugCentral","target":"Gonadotropin-releasing hormone receptor","protein":"Gonadotropin-releasing hormone receptor","activityType":"IC50"}],"modality":"small molecule","drugClass":"Gonadotropin Releasing Hormone Receptor Antagonist [EPC]","explanation":"Relugolix works by binding to the gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. This binding action reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn decreases the production of testosterone. This mechanism of action is unique and provides a new approach to treating conditions such as prostate cancer, uterine fibroids, and endometriosis.","oneSentence":"Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors.","technicalDetail":"Relugolix is a competitive antagonist of the GnRH receptor, which results in a decrease in LH and FSH release. This decrease in hormone release leads to a reduction in testosterone production. The nonpeptide structure of relugolix allows for oral administration and provides a convenient treatment option for patients."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_wikipedia":{"title":"Relugolix","extract":"Relugolix, sold under the brand names Orgovyx and Relumina among others, is a gonadotropin-releasing hormone antagonist medication which is used in the treatment of prostate cancer, uterine fibroids and endometriosis. It is taken by mouth.","wiki_history":"==History==\nRelugolix was first described in 2004. Relugolix was approved for the treatment of prostate cancer in the United States on 18 December 2020.","wiki_medical_uses":"==Medical uses==\nRelugolix is approved in the United States, Canada and the United Kingdom for the treatment of prostate cancer, in Japan for the treatment of uterine fibroids (uterine leiomyoma) and in the United Kingdom for endometriosis.\n\n===Available forms===\nRelugolix is available in the form of 40 and 120 mg oral tablets.","wiki_society_and_culture":"==Society and culture==\n=== Names ===\nRelugolix is the generic name of the drug and its , , and . It is also known by its former developmental code names RVT-601 and TAK-385.\n\n=== Legal status ===\nIn February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Orgovyx, intended for the treatment of prostate cancer. Relugolix was approved for medical use in the European Union in April 2022, and in the United Kingdom in July 2022 (although not available in NHS England until August 2024)."},"commercial":{"launchDate":"2020","revenueYear":2025,"annualCostUS":"$","_launchSource":"DrugCentral (FDA 2020-12-18, MYOVANT SCIENCES)","annualRevenue":421,"revenueSource":"Verified: Pfizer 8-K FY2025","currentRevenue":"$21.2B","revenueCurrency":"USD","patientPopulation":"For adults with advanced prostate cancer","peakSalesEstimate":"$21.2B","revenueConfidence":"verified","revenueExtractedAt":"2026-04-01T11:46:21.772620","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5432","fields":["approvals","synonyms","ATC","pharmacokinetics","patents","indications","contraindications","interactions","targets"],"source":"DrugCentral"},{"id":2,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=relugolix","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=relugolix","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=relugolix","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":6,"url":"https://en.wikipedia.org/wiki/relugolix","fields":["history","overview"],"source":"Wikipedia"},{"id":7,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/","fields":["timeline","launchDate"],"source":"FDA Drugs@FDA"},{"id":8,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":9,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":10,"url":"https://www.whocc.no/atc_ddd_index/","fields":["classification"],"source":"WHO ATC/DDD Index"},{"id":11,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_emaChecked":true,"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:44:33.229008+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Lupron","company":"Not specified","advantage":"Long history and wide use, oral alternative to Orgovyx"},{"name":"Eligard","company":"Not specified","advantage":"Flexibility in dosing duration, subcutaneous injection"},{"name":"Trelstar","company":"Not specified","advantage":"Unique short- and long-acting formulations, caters to diverse patient needs"},{"name":"Camcevi","company":"Not specified","advantage":"Oral formulation, alternative to traditional GnRH agonists"}],"genericName":"relugolix","indications":{"approved":[{"name":"Abnormal uterine bleeding due to uterine fibroid","source":"DrugCentral","snomedId":16754891000119106,"regulator":"FDA"},{"name":"Lower abdominal pain","source":"DrugCentral","snomedId":54586004,"regulator":"FDA"},{"name":"Malignant tumor of prostate","source":"DrugCentral","snomedId":399068003,"regulator":"FDA"},{"name":"Menorrhagia","source":"DrugCentral","snomedId":386692008,"regulator":"FDA"},{"name":"Pain associated with endometriosis","source":"DrugCentral","snomedId":129103003,"regulator":"FDA"},{"name":"Uterine fibroids","source":"DrugCentral","snomedId":95315005,"regulator":"FDA"}]},"_drugCentral":{"patents":[{"number":"10449191","expires":"2037-09-29"},{"number":"10786501","expires":"2037-09-29"},{"number":"11033551","expires":"2037-09-29"},{"number":"11583526","expires":"2037-09-29"},{"number":"10350170","expires":"2036-02-25"},{"number":"9346822","expires":"2024-02-17"},{"number":"8735401","expires":"2024-02-04"},{"number":"7300935","expires":"2024-01-28"},{"number":"8058280","expires":"2024-01-28"}],"targets":[{"gene":"GNRHR","target":"Gonadotropin-releasing hormone receptor","protein":"Gonadotropin-releasing hormone receptor","activityType":"IC50","activityUnit":"","activityValue":9.92}],"atcCodes":["H01CC54","L02BX04"],"synonyms":["relugolix","TAK-385","orgovyx","relumina","RVT 601"],"approvals":[{"date":"2019-08-01","orphan":false,"company":"Takeda Pharmaceutical Company Limited","regulator":"PMDA"},{"date":"2020-12-18","orphan":false,"company":"MYOVANT SCIENCES","regulator":"FDA"},{"date":"2021-07-16","orphan":false,"company":"Gedeon Richter Plc.","regulator":"EMA"}],"properties":{"S":{"name":"Water solubility","units":"mg/mL","value":0.04},"BDDCS":{"name":"Biopharmaceutical Drug Disposition Classification System","units":"","value":2}},"drugClasses":[],"identifiers":{"MMSL":"342118","NDDF":"018596","UNII":"P76B05O5V6","VANDF":"4039939","INN_ID":"9628","RXNORM":"2472778","UMLSCUI":"C3896936","ChEMBL_ID":"CHEMBL1800159","KEGG_DRUG":"D10888","DRUGBANK_ID":"DB11853","PUBCHEM_CID":"10348973","SNOMEDCT_US":"1144477009","IUPHAR_LIGAND_ID":"5586","MESH_SUPPLEMENTAL_RECORD_UI":"C561634"},"indications":[{"name":"Abnormal uterine bleeding due to uterine fibroid","source":"DrugCentral","umlsCui":"C5190725","snomedId":16754891000119106},{"name":"Lower abdominal pain","source":"DrugCentral","umlsCui":"C0232495","snomedId":54586004},{"name":"Malignant tumor of prostate","source":"DrugCentral","umlsCui":"C0376358","snomedId":399068003},{"name":"Menorrhagia","source":"DrugCentral","umlsCui":"C0025323","snomedId":386692008},{"name":"Pain associated with endometriosis","source":"DrugCentral","umlsCui":"C0014175","snomedId":129103003},{"name":"Uterine fibroids","source":"DrugCentral","umlsCui":"C0042133","snomedId":95315005}],"formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","status":"NDA","tradeName":"Myfembree"},{"form":"TABLET, FILM COATED","route":"ORAL","status":"NDA","tradeName":"Orgovyx"}],"offLabelUses":[],"drugCentralId":5432,"drugInteractions":[],"contraindications":[]},"_drugWebsite":{"url":"https://www.orgovyx.com","content":"Important Safety Information\nPrescribing Information\nPatient Information\nInformación del Paciente\nFor Healthcare Professionals\nAbout ORGOVYX\nStarting ORGOVYX\nCost & Support\nPatient Stories\nPatient Resources\nAdvanced Prostate Cancer\nQuestions? Call\n1-833-674-6899\n\nFor adults with advanced prostate cancer\n\nA different kind of ADT\ntreatment — A PILL. \nNot an injection.\nLearn More\nNot actual patient.\nIMPORTANT SAFETY INFORMATION & USE\n\nDo not take ORGOVYX if you have had a severe allergic reaction to relugolix or any of the ingredients in ORGOVYX.\n\nWhat should I tell my healthcare provider before taking ORGOVYX?\n\nTell your healthcare provider about all of your medical conditions, including if you:\n\nHave any heart problems, including a condition called long QT syndrome.\nAre pregnant or plan to become pregnant. ORGOVYX can harm your unborn baby and cause loss of pregnancy (miscarriage).\nHave a partner who is pregnant or may become pregnant.\nMales who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with ORGOVYX and for 2 weeks after the last dose of ORGOVYX.\nAre breastfeeding or plan to breastfeed. It is not known if ORGOVYX passes into your breast milk.\n\nTell your healthcare provider about all the medicines or treatments you receive, including: prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking ORGOVYX with certain other medicines can affect how ORGOVYX works or may cause side effects.\n\nYou should not start or stop any medicine before you talk with your healthcare provider who prescribed ORGOVYX.\n\nWhat are the possible side effects of ORGOVYX?\n\nSerious side effects of ORGOVYX include:\n\nChanges in the electrical activity of your heart (QT prolongation). Your healthcare provider may check your body salts (electrolytes) and the electrical activity of your heart during treatment with ORGOVYX. Tell your healthcare provider right away if you get any signs or symptoms of Q"},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07025369","phase":"PHASE2","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-25","conditions":"Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT07182279","phase":"PHASE1, PHASE2","title":"Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-08-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":29},{"nctId":"NCT06330805","phase":"PHASE2","title":"Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-08-12","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT06463457","phase":"PHASE2","title":"Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atish Choudhury, MD","startDate":"2024-12-13","conditions":"Prostate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate Cancer","enrollment":33},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT06130995","phase":"PHASE1","title":"Relugolix + Enzalutamide Study in High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2024-12-26","conditions":"Androgen Deprivation Therapy, Locally Advanced Prostate Cancer","enrollment":46},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT07440043","phase":"","title":"Relugolix for Endometriosis Associated Pain","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-02-25","conditions":"Endometriosis, Endometriosis-related Pain, Pelvic Pain Syndrome","enrollment":33},{"nctId":"NCT06650579","phase":"PHASE3","title":"REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-31","conditions":"Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":72},{"nctId":"NCT07100782","phase":"PHASE3","title":"Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-12-08","conditions":"Endometriosis, Pelvic Pain","enrollment":130},{"nctId":"NCT06111313","phase":"PHASE2","title":"The University of Miami Adapt (UAdapt) Trial","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-11-06","conditions":"Prostate Cancer","enrollment":130},{"nctId":"NCT05320406","phase":"PHASE2","title":"RElugolix VErsus LeUprolide Cardiac Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-06-06","conditions":"Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8","enrollment":94},{"nctId":"NCT06631521","phase":"PHASE1","title":"Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer","status":"RECRUITING","sponsor":"AdventHealth","startDate":"2024-10-22","conditions":"Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery","enrollment":30},{"nctId":"NCT06671548","phase":"PHASE3","title":"Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-01-15","conditions":"Heavy Menstrual Bleeding, Uterine Fibroids","enrollment":120},{"nctId":"NCT06397703","phase":"PHASE2","title":"ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-04-16","conditions":"Prostate Cancer","enrollment":392},{"nctId":"NCT06111781","phase":"PHASE2","title":"The SUGAR Study; SBRT and Relugolix) for Prostate Cancer","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-04-15","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT06734130","phase":"PHASE2","title":"Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-01-10","conditions":"Metastatic Castration Sensitive Prostate Cancer","enrollment":25},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":"Prostate Adenocarcinoma","enrollment":2050},{"nctId":"NCT05053152","phase":"PHASE2","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-04-20","conditions":"Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma","enrollment":194},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":"Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":2753},{"nctId":"NCT07111247","phase":"PHASE4","title":"Insights in Endocervical Mucus Secretion","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-01-02","conditions":"Cervical Mucus","enrollment":15},{"nctId":"NCT04756037","phase":"PHASE3","title":"Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2021-03-18","conditions":"Contraception","enrollment":1020},{"nctId":"NCT07302451","phase":"PHASE2","title":"REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-12-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":50},{"nctId":"NCT06531499","phase":"PHASE1","title":"A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-11","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":106},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT05241860","phase":"PHASE2","title":"Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-11-21","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":79},{"nctId":"NCT06462014","phase":"","title":"Description of Relugolix Use in Patients With Prostate Cancer Within the VHA","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-06-19","conditions":"Prostate Cancer","enrollment":507},{"nctId":"NCT05189457","phase":"PHASE2","title":"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-01-25","conditions":"Prostate Cancer, Stage IV Prostate Cancer","enrollment":32},{"nctId":"NCT05628363","phase":"NA","title":"Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-18","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":28},{"nctId":"NCT07216248","phase":"PHASE2","title":"Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-10-27","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":160},{"nctId":"NCT06499870","phase":"PHASE2","title":"Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-09-06","conditions":"Prostate Adenocarcinoma","enrollment":50},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT05538689","phase":"PHASE4","title":"Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-11-20","conditions":"Metrorrhagia, Pelvic Pain, Menorrhagia","enrollment":0},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":0},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT06279195","phase":"PHASE2","title":"Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment","status":"WITHDRAWN","sponsor":"Endeavor Health","startDate":"2024-06-01","conditions":"Pelvic Pain","enrollment":0},{"nctId":"NCT07142967","phase":"NA","title":"Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-08-15","conditions":"Intraprostatic Prostate Cancer","enrollment":28},{"nctId":"NCT05739123","phase":"","title":"Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring","status":"RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2023-05-08","conditions":"Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk","enrollment":728},{"nctId":"NCT05605964","phase":"PHASE3","title":"Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2023-01-25","conditions":"Prostate Cancer","enrollment":387},{"nctId":"NCT04666129","phase":"PHASE1","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2021-02-18","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer","enrollment":48},{"nctId":"NCT06953076","phase":"","title":"Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-05-02","conditions":"Uterine Bleeding, Uterine Leiomyomas, Uterine Hemorrhage","enrollment":111},{"nctId":"NCT05467176","phase":"","title":"A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2022-10-04","conditions":"Prostate Cancer","enrollment":999},{"nctId":"NCT05765500","phase":"PHASE2","title":"RecoverPC: Relugolix vs GnRH Agonist in Quality of Life","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-12","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":110},{"nctId":"NCT05862272","phase":"PHASE3","title":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","status":"RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2023-08-14","conditions":"Uterine Fibroids, Endometriosis","enrollment":1000},{"nctId":"NCT05739136","phase":"","title":"MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2025-04-30","conditions":"Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk","enrollment":530},{"nctId":"NCT07069465","phase":"EARLY_PHASE1","title":"Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging","status":"COMPLETED","sponsor":"Urology Clinics of North Texas","startDate":"2024-06-15","conditions":"Prostate Cancer","enrollment":10},{"nctId":"NCT06439524","phase":"PHASE3","title":"The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Main Line Health","startDate":"2024-08-15","conditions":"Endometriosis","enrollment":110},{"nctId":"NCT04523207","phase":"PHASE2","title":"A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-08-19","conditions":"Prostatic Neoplasms","enrollment":108},{"nctId":"NCT05679388","phase":"PHASE1","title":"A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2023-02-13","conditions":"Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT03751124","phase":"PHASE3","title":"Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2018-10-16","conditions":"Uterine Leiomyoma, Uterine Fibroids","enrollment":229},{"nctId":"NCT03412890","phase":"PHASE3","title":"LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-10-19","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":477},{"nctId":"NCT06312761","phase":"PHASE1, PHASE2","title":"Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2024-06-01","conditions":"Hypogonadism, Male","enrollment":10},{"nctId":"NCT06129851","phase":"PHASE2","title":"Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2023-11-20","conditions":"Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8","enrollment":90},{"nctId":"NCT03654274","phase":"PHASE3","title":"SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2018-05-22","conditions":"Endometriosis","enrollment":802},{"nctId":"NCT03103087","phase":"PHASE3","title":"LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-06-14","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":382},{"nctId":"NCT03049735","phase":"PHASE3","title":"LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-26","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":388},{"nctId":"NCT03085095","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-18","conditions":"Prostate Cancer","enrollment":1134},{"nctId":"NCT04714554","phase":"PHASE1","title":"A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2021-01-06","conditions":"Healthy","enrollment":43},{"nctId":"NCT04978688","phase":"PHASE1","title":"Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2016-06-16","conditions":"Healthy","enrollment":48},{"nctId":"NCT03204331","phase":"PHASE3","title":"SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-11-01","conditions":"Endometriosis Related Pain","enrollment":623},{"nctId":"NCT03204318","phase":"PHASE3","title":"SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-12-07","conditions":"Endometriosis Related Pain","enrollment":638},{"nctId":"NCT03931915","phase":"PHASE3","title":"Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis","status":"COMPLETED","sponsor":"ASKA Pharmaceutical Co., Ltd.","startDate":"2019-05-08","conditions":"Endometriosis","enrollment":335},{"nctId":"NCT02655237","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-05","conditions":"Uterine Fibroids","enrollment":281},{"nctId":"NCT02655224","phase":"PHASE3","title":"A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-26","conditions":"Uterine Fibroids","enrollment":65},{"nctId":"NCT02141659","phase":"PHASE1","title":"A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-05-01","conditions":"Hormone Treatment-naïve Participants With Prostate Cancer","enrollment":43},{"nctId":"NCT02083185","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2014-03-26","conditions":"Prostate Cancer","enrollment":136},{"nctId":"NCT02792062","phase":"PHASE1","title":"A Food Effect Study of TAK-385 Final Formulation","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-07-04","conditions":"Japanese Premenopausal Healthy Adult Women","enrollment":12},{"nctId":"NCT02135445","phase":"PHASE2","title":"Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Prostate Cancer","enrollment":103},{"nctId":"NCT02252354","phase":"PHASE1","title":"TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-09","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT02396147","phase":"PHASE1","title":"Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03","conditions":"Healthy Volunteers","enrollment":54},{"nctId":"NCT02093390","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2014-03","conditions":"Prostate Cancer, Endometriosis","enrollment":40},{"nctId":"NCT01452685","phase":"PHASE2","title":"A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-03","conditions":"Endometriosis","enrollment":397},{"nctId":"NCT01458301","phase":"PHASE2","title":"Efficacy and Safety of TAK-385 in the Treatment of Endometriosis","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Endometriosis","enrollment":487},{"nctId":"NCT01452659","phase":"PHASE2","title":"Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Uterine Fibroids","enrollment":216}],"_emaApprovals":[{"date":"10/05/2022","name":"orgovyx","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[{"role":"Manufacturer","site":"Sumitomo Pharma America, Inc.","location":"","operator":"Sumitomo Pharma America, Inc."}],"molecularData":{"oral":true,"chemblId":"CHEMBL1800159","moleculeType":"Small molecule","molecularWeight":"623.64"},"administration":{"route":"Oral","formulation":"relugolix 120 MG Oral Tablet [Orgovyx]; estradiol 1 MG / norethindrone acetate 0.5 MG / relugolix 40 MG Oral Tablet [Myfembree]; relugolix 120 MG Oral Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","tradeName":"Myfembree"},{"form":"TABLET, FILM COATED","route":"ORAL","tradeName":"Orgovyx"}]},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"MMSL":"342118","NDDF":"018596","UNII":"P76B05O5V6","VANDF":"4039939","INN_ID":"9628","RXNORM":"2472778","UMLSCUI":"C3896936","chemblId":"CHEMBL1800159","ChEMBL_ID":"CHEMBL1800159","KEGG_DRUG":"D10888","DRUGBANK_ID":"DB11853","PUBCHEM_CID":"10348973","SNOMEDCT_US":"1144477009","IUPHAR_LIGAND_ID":"5586","MESH_SUPPLEMENTAL_RECORD_UI":"C561634"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"2004-present","_source":"Wikipedia","companyName":"Name not explicitly mentioned","relationship":"Originator"},{"notes":"Approved for the treatment of prostate cancer in the United States on 18 December 2020","period":"2020-present","_source":"Wikipedia","companyName":"Name not explicitly mentioned","relationship":"Acquirer"},{"notes":"Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in February 2022","period":"2022-present","_source":"Wikipedia","companyName":"European Medicines Agency","relationship":"Regulator"}],"pharmacokinetics":{"source":"FDA label","clearance":"8 L/h"},"publicationCount":240,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:58:27.672533+00","atcClassification":{"atcCode":"L02BX04","atcName":"relugolix"},"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"MYOVANT SCIENCES","companyId":"myovant-sciences","modality":"small molecule","firstApprovalDate":"2020","enrichmentLevel":4,"visitCount":5,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-03-30T00:00:00.000Z","mah":"SUMITOMO PHARMA AM","brand_name_local":null,"application_number":"NDA214621"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-08-27T00:00:00.000Z","mah":"SUMITOMO PHARMA AM","brand_name_local":null,"application_number":"NDA214846"},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8058280","territory":"US","patent_type":null,"expiry_date":"2024-01-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7300935","territory":"US","patent_type":null,"expiry_date":"2024-01-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8735401","territory":"US","patent_type":null,"expiry_date":"2024-02-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9346822","territory":"US","patent_type":null,"expiry_date":"2024-02-17T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10350170","territory":"US","patent_type":null,"expiry_date":"2036-02-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10786501","territory":"US","patent_type":null,"expiry_date":"2037-09-29T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11583526","territory":"US","patent_type":null,"expiry_date":"2037-09-29T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11033551","territory":"US","patent_type":null,"expiry_date":"2037-09-29T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10449191","territory":"US","patent_type":null,"expiry_date":"2037-09-29T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":15,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:44:33.229008+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}